伊芙美尔医疗 ICCC 深 沪
已收盘 02-06 16:00:00 美东时间
6.24
+0.132
+2.16%
华盛通- 最 高6.38
- 今 开6.15
- 成交量 7768股
- 最 低 6.0593
- 昨 收 6.108
- 总市值 5644.61万
- 52周最高 7.60
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 4.28
- 委 比 -92.49%
- 总股本 904.59万
- 历史最高 13.20
- 量 比 0.36
- 振 幅 5.25%
- 历史最低 3.19
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmuCell Sets New Executive Pay Packages and Performance Incentives
ImmuCell Sets New Executive Pay Packages and Performance Incentives ImmuCell Corporation has announced new employment agreements for key executives, effective January 27, 2026. Chief Financial Officer Timothy C. Fiori will receive an annual base salary of $315,000, while Senior Vice President of Sal
02-03 06:23
ImmuCell Corporation beschließt neue Vergütungsvereinbarungen für Führungskräfte
ImmuCell Corporation beschließt neue Vergütungsvereinbarungen für Führungskräfte ImmuCell Corporation hat neue Vergütungsvereinbarungen für CFO Timothy C. Fiori und Senior Vice President Bobbi Jo Brockmann bekannt gegeben. Ab dem 27. Januar 2026 erhalten Fiori ein Jahresgrundgehalt von 315.000 US-Do
02-03 06:23
ImmuCell reports preliminary Q4 results
ImmuCell press release (ICCC): Q4 Revenue of $7.6M. International sales were $0.6 million in 2025, a 52.6% decline compared to 2024 Tri-Shield sales were $6.0 million in 2025, a 41.3% increase compare...
01-09 05:28
ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary,
01-09 05:10
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
ImmuCell Corp reported preliminary Q4 2025 sales of $7.6 million, down 1.6% from Q4 2024, with domestic sales up 8.7% to $7.0 million and international sales down 52.6% to $0.6 million. Its Tri-Shield® product line saw strong growth at 41.3%, while Dual-Force® sales dropped 53.0%. Full-year 2025 sales rose 4.3% to $27.6 million, driven by a 26.5% increase in Tri-Shield® sales to $19.9 million. The company plans to focus on expanding First Defe...
01-08 21:05
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
ImmuCell Corporation has scheduled a conference call for January 9, 2026, at 9:00 AM ET to discuss its strategic shift to the First Defense® product line and away from Re-Tain®. The company will also present its unaudited sales results for Q4 and the full year 2025, which will be released after the market closes on January 8, 2026. A replay of the call will be available until January 16, 2026. Additional financial results and a follow-up call are...
01-07 13:10
ImmuCell Increasing First Defense Field Sales Force By 50%, Expanding First Defense Production Capabilities After Receiving FDA's Incomplete Letter For Its Re-Tain New Animal Drug Application
ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete
2025-12-25 02:07
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
ImmuCell Corporation received an Incomplete Letter from the FDA for its Re-Tain® NADA application, prompting the company to pause further investment in Re-Tain® and focus on expanding its First Defense® franchise. ImmuCell will increase its First Defense® field sales force by 50% and enhance manufacturing capabilities to capitalize on its $900 million worldwide market potential. The company anticipates a non-cash impairment write-down of approxim...
2025-12-24 18:05
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
ImmuCell Corporation (Nasdaq: ICCC) plans to release its unaudited Q3 2025 financial results after market close on November 13, 2025. A conference call to discuss the results is scheduled for November 14, 2025 at 9:00 AM ET. Participants can join by dialing (844) 855-9502 (toll-free) or (412) 317-5499 (international). A replay will be available until November 21, 2025 at (877) 344-7529 (toll-free) or (412) 317-0088 (international) using replay co...
2025-11-06 21:05
ImmuCell Announces New CEO and Leadership Changes
The latest update is out from Immucell ( ($ICCC) ). ImmuCell Corporation announ...
2025-11-05 05:45
